Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis
Our results show guttiferone E to be a promising, novel and potent antitumor drug candidate for osimertinib-resistant lung cancer with EGFR L858R/T790M mutations.
Authors
- Islauddin Khan (ORCID: https://orcid.org/0000-0002-1352-7691)
- Satyanarayan Dev (ORCID: https://orcid.org/0000-0003-2667-433X)
- Jennyfer Andrea Aldana Mejía (ORCID: https://orcid.org/0000-0003-0736-1899)
- Aakash Nathani (ORCID: https://orcid.org/0000-0003-1852-6548)
- Jairo Kenupp Bastos (ORCID: https://orcid.org/0000-0001-8641-9686)
- Matheus Hikaru Tanimoto (ORCID: https://orcid.org/0000-0002-1063-3026)
- Arun K. Rishi (ORCID: https://orcid.org/0000-0001-8611-9923)
- Mandip Singh
- Aline Mayrink DE Miranda
Institutions
- Universidade de São Paulo (BR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-09-30
- DOI
- https://doi.org/10.21873/anticanres.17248
- Citations
- 5
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health
- National Institute on Minority Health and Health Disparities